多参数MRI阴性患者中哪些可安全避免前列腺穿刺
该研究纳入135例穿刺前多参数MRI阴性(PI-RADS<3)的男性,评估临床显著前列腺癌检出率。结果显示,MRI阴性且PSA密度<0.15 ng/ml/cc并有既往阴性穿刺史者,重复穿刺均未检出临床显著前列腺癌;而初次穿刺者即使MRI阴性仍应考虑穿刺。
要点
- MRI阴性且PSA密度<0.15 ng/ml/cc且有既往阴性穿刺史者可安全避免重复穿刺。
- 初次穿刺男性即使MRI阴性仍应考虑前列腺穿刺,尤其PSA密度>0.15 ng/ml/cc者。
- MRI阴性者总体临床显著前列腺癌检出率为18%,需结合PSA密度和穿刺史分层。
核心结论
- MRI阴性、PSA密度<0.15 ng/ml/cc且有既往阴性穿刺史的患者可安全避免重复穿刺。
- 初次穿刺男性无论MRI是否阴性均应考虑前列腺穿刺,尤其PSA密度>0.15 ng/ml/cc者。
研究设计与样本
- 回顾性分析2011年10月至2017年3月连续1149例前列腺穿刺男性,其中135例穿刺前多参数MRI阴性(PI-RADS评分<3)。
- 临床显著前列腺癌定义为Grade Group≥2。
主要发现
- 总体前列腺癌和临床显著前列腺癌检出率分别为38%和18%。
- 临床显著前列腺癌患者前列腺体积更小(p=0.004)、PSA密度更高(p=0.02)且无既往阴性穿刺史(p=0.01)。
- PSA密度<0.15 ng/ml/cc(p<0.001)和既往阴性穿刺(p=0.005)是穿刺无临床显著前列腺癌的独立预测因素。
- MRI阴性仅此一项、联合PSA密度<0.15 ng/ml/cc、以及再联合既往阴性穿刺三组中,临床显著前列腺癌发生率分别为18%、10%和0%。
关键数值与推荐
- PSA密度<0.15 ng/ml/cc为独立预测因素(p<0.001),既往阴性穿刺为独立预测因素(p=0.005)。
- MRI阴性且PSA密度<0.15 ng/ml/cc且有既往阴性穿刺史者占32%,重复穿刺均未检出临床显著前列腺癌。
临床怎么用
- 对MRI阴性且有既往阴性穿刺史者,若PSA密度<0.15 ng/ml/cc可考虑安全避免重复穿刺。
- 对初次穿刺男性,即使MRI阴性仍应建议前列腺穿刺,尤其PSA密度>0.15 ng/ml/cc时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to determine whether there is a subset of men who can avoid prostate biopsy based on multiparametric magnetic resonance imaging and clinical characteristics. MATERIALS AND METHODS: Of 1,149 consecutive men who underwent prostate biopsy from October 2011 to March 2017, 135 had prebiopsy negative multiparametric magnetic resonance imaging with PI-RADS™ (Prostate Imaging Reporting and Data System) score less than 3. The detection rate of clinically significant prostate cancer was evaluated according to prostate specific antigen density and prior biopsy history. Clinically significant prostate cancer was defined as Grade Group 2 or greater. Multivariable logistic regression analysis was performed to identify predictors of nonclinically significant prostate cancer on biopsy. RESULTS: The prostate cancer and clinically significant prostate cancer detection rates were 38% and 18%, respectively. Men with biopsy detected, clinically significant prostate cancer had a smaller prostate (p = 0.004), higher prostate specific antigen density (p = 0.02) and no history of prior negative biopsy (p = 0.01) compared to the nonclinically significant prostate cancer cohort. Prostate specific antigen density less than 0.15 ng/ml/cc (p <0.001) and prior negative biopsy (p = 0.005) were independent predictors of absent clinically significant prostate cancer on biopsy. The negative predictive value of multiparametric magnetic resonance imaging for biopsy detection of clinically significant prostate cancer improved with decreasing prostate specific antigen density, primarily in men with prior negative biopsy (p = 0.001) but not in biopsy naïve men. Of the men 32% had the combination of negative multiparametric magnetic resonance imaging, prostate specific antigen density less than 0.15 ng/ml/cc and negative prior biopsy, and none had clinically significant prostate cancer on repeat biopsy. The incidence of biopsy identified, clinically significant prostate cancer was 18%, 10% and 0% in men with negative multiparametric magnetic resonance imaging only, men with negative multiparametric magnetic resonance imaging and prostate specific antigen density less than 0.15 ng/ml/cc, and men with negative multiparametric magnetic resonance imaging, prostate specific antigen density less than 0.15 ng/ml/cc and negative prior biopsy, respectively. CONCLUSIONS: We propose that a subset of men with negative multiparametric magnetic resonance imaging, prostate specific antigen density less than 0.15 ng/ml/cc and prior negative biopsy may safely avoid rebiopsy. Conversely prostate biopsy should be considered in biopsy naïve men regardless of negative multiparametric magnetic resonance imaging, particularly those with prostate specific antigen density greater than 0.15 ng/ml/cc.
引用
- Oishi M, Shin T, Ohe C, et al. Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer? J Urol. 2019. PMID: 30189186. doi:10.1016/j.juro.2018.08.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。